{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:21:49Z","timestamp":1784938909227,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.kint.2025.10.003","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:22:32Z","timestamp":1767716552000},"page":"2-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SGLT-2 inhibition in pediatric CKD: advances, challenges, and opportunities"],"prefix":"10.1016","volume":"109","author":[{"given":"Franz","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.10.003_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.kint.2025.09.009","article-title":"Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023","volume":"91","author":"Smoyer","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.10.003_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"for the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.10.003_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.10.003_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.10.003_bib2","article-title":"Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy and safety","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.kint.2025.10.003_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/597920","article-title":"Interactions between cytokines, congenital anomalies of kidney and urinary tract and chronic kidney disease","volume":"2013","author":"Sim\u00f5es e Silva","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.kint.2025.10.003_bib4","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/j.ekir.2025.07.004","article-title":"GDF-15 and uEGF independently associate with CKD progression in children","volume":"10","author":"Bartels","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.10.003_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S2352-4642(23)00049-4","article-title":"Urinary DKK3 as a biomarker for short-term kidney function decline in children with chronic kidney disease: an observational cohort study","volume":"7","author":"Speer","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.kint.2025.10.003_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11906-024-01308-1","article-title":"Hypertension and cardiovascular risk among children with chronic kidney disease","volume":"26","author":"Larkins","year":"2024","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kint.2025.10.003_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-024-08021-z","article-title":"Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies","volume":"25","author":"Schaefer","year":"2024","journal-title":"Trials"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:32:14Z","timestamp":1778941934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825008452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0085253825008452"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.10.003","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT-2 inhibition in pediatric CKD: advances, challenges, and opportunities","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}